サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1541099

ウイルス不活性化市場レポート：製品、用途、最終用途、地域別 2024-2032

Viral Inactivation Market Report by Product, Application, End Use, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 138 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.41円
ウイルス不活性化市場レポート：製品、用途、最終用途、地域別 2024-2032
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 138 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ウイルス不活性化市場の世界市場規模は2023年に6億3,560万米ドルに達しました。今後、IMARC Groupは、市場は2032年までに13億9,080万米ドルに達し、2024年から2032年の間に8.8％の成長率（CAGR）を示すと予測しています。

バイオ治療製品はウイルスを含むか、製造過程で汚染される可能性があります。ウイルスは感染性粒子であり、細胞に侵入して増殖し、様々な病気を引き起こします。そのため、ウイルスの不活化は、コートタンパク質を阻害し、ウイルス内の核酸を分解するために広く用いられています。現在、ウイルスを不活性化する方法は、ウイルスの特性やバイオ治療製品のタイプに応じて、世界中でさまざまな方法が利用できます。例えば、殺菌（UVC）光照射は、病院やその他の重要な公共・軍事環境におけるウイルスの不活化に役立っています。

ウイルス不活性化市場動向：

ヒト血液は、生命を脅かす疾患の予防と治療に役立つ医薬品の供給源です。血漿由来の医薬品を介した血液媒介ウイルスの伝播に関する懸念の高まりは、世界中でウイルス不活化の必要性に影響を与えている重要な要因の一つです。現在では、血漿由来のタンパク質溶液の安全性を保証するために、いくつかのウイルス不活性化手順が用いられています。さらに、多くの国々の管理機関は、バイオ治療製品の開発の早い段階で厳しい規制基準を導入しています。このような基準により、製品の品質、安全性、有効性を確保し、交差汚染のリスクを低減するために、ウイルス不活化に対する需要が高まっています。これとは別に、改良されたウイルス不活化技術や製品は、腸内ウイルスの伝播を制御し、製品の安全性を保証するために、飲食品（F&B）産業で採用されています。これは、超臨界流体、ガスプラズマ、パルス電界のような新しい物理的方法の開発と相まって、ウイルス不活化の信頼性、利便性、適合性を高め、市場を牽引すると予想されます。

本レポートで扱う主な質問

  • 世界のウイルス不活性化市場はこれまでどのように推移し、今後どのように推移するのか？
  • COVID-19が世界のウイルス不活性化市場に与えた影響は？
  • 主要地域市場とは？
  • 製品別の市場内訳は？
  • 用途別の市場内訳は？
  • 最終用途別の市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 業界の主要な促進要因と課題は何か？
  • 世界のウイルス不活性化市場の構造と主要企業は？
  • 業界の競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界のウイルス不活性化市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：製品別

  • 試薬とキット
    • 市場動向
    • 市場予測
  • システム
    • 市場動向
    • 市場予測
  • サービス
    • 市場動向
    • 市場予測

第7章 市場内訳：用途別

  • ワクチンと治療薬
    • 市場動向
    • 市場予測
  • 幹細胞製品
    • 市場動向
    • 市場予測
  • 血液および血液製剤
    • 市場動向
    • 市場予測
  • 組織および組織製品
    • 市場動向
    • 市場予測
  • 細胞および遺伝子治療
    • 市場動向
    • 市場予測

第8章 市場内訳：最終用途別

  • 製薬・バイオテクノロジー企業
    • 市場動向
    • 市場予測
  • CRO（医薬品開発業務受託機関）
    • 市場動向
    • 市場予測
  • 学術研究機関
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Charles River Laboratories
    • Merck KGaA
    • Parker Hannifin Corp
    • Rad Source Technologies
    • Sartorius AG
    • SGS SA
    • Terumo Corporation
    • Texcell
    • Vironova AB
    • WuXi AppTec
図表

List of Figures

  • Figure 1: Global: Viral Inactivation Market: Major Drivers and Challenges
  • Figure 2: Global: Viral Inactivation Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Viral Inactivation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Viral Inactivation Market: Breakup by Product (in %), 2023
  • Figure 5: Global: Viral Inactivation Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Viral Inactivation Market: Breakup by End Use (in %), 2023
  • Figure 7: Global: Viral Inactivation Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Viral Inactivation (Reagents and Kits) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Viral Inactivation (Reagents and Kits) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Viral Inactivation (Systems) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Viral Inactivation (Systems) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Viral Inactivation (Services) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Viral Inactivation (Services) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Viral Inactivation (Vaccines and Therapeutics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Viral Inactivation (Vaccines and Therapeutics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Viral Inactivation (Stem Cell Products) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Viral Inactivation (Stem Cell Products) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Viral Inactivation (Blood and Blood Products) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Viral Inactivation (Blood and Blood Products) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Viral Inactivation (Tissue and Tissue Products) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Viral Inactivation (Tissue and Tissue Products) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Viral Inactivation (Cellular and Gene Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Viral Inactivation (Cellular and Gene Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Viral Inactivation (Pharmaceutical and Biotechnology Companies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Viral Inactivation (Pharmaceutical and Biotechnology Companies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Viral Inactivation (CROs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Viral Inactivation (CROs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Viral Inactivation (Academic and Research Institutes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Viral Inactivation (Academic and Research Institutes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Viral Inactivation (Other End Uses) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Viral Inactivation (Other End Uses) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: North America: Viral Inactivation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: North America: Viral Inactivation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: United States: Viral Inactivation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: United States: Viral Inactivation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Canada: Viral Inactivation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Canada: Viral Inactivation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Asia-Pacific: Viral Inactivation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Asia-Pacific: Viral Inactivation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: China: Viral Inactivation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: China: Viral Inactivation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Japan: Viral Inactivation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Japan: Viral Inactivation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: India: Viral Inactivation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: India: Viral Inactivation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: South Korea: Viral Inactivation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: South Korea: Viral Inactivation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Australia: Viral Inactivation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Australia: Viral Inactivation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Indonesia: Viral Inactivation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Indonesia: Viral Inactivation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Others: Viral Inactivation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Others: Viral Inactivation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Europe: Viral Inactivation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Europe: Viral Inactivation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Germany: Viral Inactivation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Germany: Viral Inactivation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: France: Viral Inactivation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: France: Viral Inactivation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: United Kingdom: Viral Inactivation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: United Kingdom: Viral Inactivation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Italy: Viral Inactivation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Italy: Viral Inactivation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Spain: Viral Inactivation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Spain: Viral Inactivation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Russia: Viral Inactivation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Russia: Viral Inactivation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Others: Viral Inactivation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Others: Viral Inactivation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Latin America: Viral Inactivation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Latin America: Viral Inactivation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Brazil: Viral Inactivation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Brazil: Viral Inactivation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Mexico: Viral Inactivation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Mexico: Viral Inactivation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Others: Viral Inactivation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Others: Viral Inactivation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Middle East and Africa: Viral Inactivation Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Middle East and Africa: Viral Inactivation Market: Breakup by Country (in %), 2023
  • Figure 80: Middle East and Africa: Viral Inactivation Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Global: Viral Inactivation Industry: SWOT Analysis
  • Figure 82: Global: Viral Inactivation Industry: Value Chain Analysis
  • Figure 83: Global: Viral Inactivation Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Viral Inactivation Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Viral Inactivation Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Viral Inactivation Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 4: Global: Viral Inactivation Market Forecast: Breakup by End Use (in Million US$), 2024-2032
  • Table 5: Global: Viral Inactivation Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Viral Inactivation Market: Competitive Structure
  • Table 7: Global: Viral Inactivation Market: Key Players
目次
Product Code: SR112024A4115

The global viral inactivation market size reached US$ 635.6 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,390.8 Million by 2032, exhibiting a growth rate (CAGR) of 8.8% during 2024-2032.

Biotherapeutic products contain viruses or they can become contaminated during the production process. Viruses are infectious particles that invade cells wherein they proliferate and result in various diseases. As a result, viral inactivation is widely used to inhibit coat proteins and degrade nucleic acid within the virus. At present, different methods of viral inactivation are available across the globe according to the characteristics of the virus and the type of biotherapeutic product. For instance, germicidal (UVC) light exposure helps inactivate viruses in hospitals and other critical public and military environments.

Viral Inactivation Market Trends:

Human blood is a source of medicinal products that assists in the prevention and treatment of life-threatening diseases. Rising concerns about the transmission of blood-borne viruses through plasma-derived medicinal products represent one of the significant factors influencing the need for viral inactivation around the world. Several procedures for viral inactivation are nowadays used to assure the safety of blood plasma-derived protein solutions. Moreover, governing agencies of numerous countries are introducing stringent regulatory standards at an early stage in the development of biotherapeutic products. These standards are escalating the demand for viral inactivation to ensure the quality, safety, and efficacy of these products, thereby reducing the risk of cross-contamination. Apart from this, improved viral inactivation technologies and products are being employed in the food and beverage (F&B) industry to help control the transmission of enteric viruses and assure the safety of products. This, in confluence with the development of new physical methods like supercritical fluids, gas plasma, and pulsed electric fields, is anticipated to increase the reliability, convenience, and suitability of viral inactivation, thereby driving the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global viral inactivation market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, application and end use.

Breakup by Product:

Reagents and Kits

Systems

Services

Breakup by Application:

Vaccines and Therapeutics

Stem Cell Products

Blood and Blood Products

Tissue and Tissue Products

Cellular and Gene Therapy

Breakup by End Use:

Pharmaceutical and Biotechnology Companies

CROs

Academic and Research Institutes

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Charles River Laboratories, Merck KGaA, Parker Hannifin Corp, Rad Source Technologies, Sartorius AG, SGS SA, Terumo Corporation, Texcell, Vironova AB and WuXi AppTec.

Key Questions Answered in This Report:

  • How has the global viral inactivation market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global viral inactivation market?
  • What are the key regional markets?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end use?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global viral inactivation market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Viral Inactivation Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Reagents and Kits
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Systems
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Services
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Vaccines and Therapeutics
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Stem Cell Products
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Blood and Blood Products
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Tissue and Tissue Products
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Cellular and Gene Therapy
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End Use

  • 8.1 Pharmaceutical and Biotechnology Companies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 CROs
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Academic and Research Institutes
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Charles River Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Merck KGaA
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Parker Hannifin Corp
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Rad Source Technologies
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 SWOT Analysis
    • 14.3.5 Sartorius AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 SGS SA
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 Terumo Corporation
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Texcell
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Vironova AB
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 WuXi AppTec
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials